Retatrutide TRIUMPH-4 Phase 3: 28.7% Weight Loss — What the Data Shows

TRIUMPH-4 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating retatrutide in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity). Announced by Eli Lilly on December 11, 2025, it is one of several Phase 3 trials (TRIUMPH-1 through TRIUMPH-5) comprising the retatrutide clinical program. The trial enrolled approximately 1,600 participants across multiple sites.

At 68 weeks, participants receiving the 12mg maintenance dose of retatrutide achieved a mean body weight loss of 28.7% from baseline. This represents the largest weight reduction ever recorded in a Phase 3 clinical trial for any anti-obesity medication. The placebo group lost approximately 2.1%. A substantial proportion of participants (estimated >70%) achieved ≥20% weight loss, a clinically meaningful threshold associated with resolution of many obesity-related comorbidities.

Retatrutide's 28.7% loss exceeds: Semaglutide 2.4mg (Wegovy) at ~16.9% (STEP 1), Tirzepatide 15mg (Zepbound) at ~22.5% (SURMOUNT-1), and even retatrutide's own Phase 2 result of 24.2% at 48 weeks. The improvement from Phase 2 to Phase 3 likely reflects the longer treatment duration (68 vs 48 weeks) and optimized dose titration schedule.

Retatrutide simultaneously activates three receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (insulin potentiation, potentially fat metabolism), and GCGR (glucagon receptor — increased energy expenditure, hepatic lipid oxidation). The glucagon receptor agonism is the differentiating factor — it adds a thermogenic, energy-expenditure component absent from GLP-1-only or GLP-1/GIP dual agonists. This triple mechanism attacks energy balance from both sides: reducing intake AND increasing expenditure.

The TRIUMPH-4 safety profile was generally consistent with the GLP-1 class. The most common adverse events were gastrointestinal: nausea (~25-30%, mostly mild-to-moderate and transient), diarrhea (~15-20%), vomiting (~10-15%), and constipation (~10%). Adverse events were most frequent during dose escalation and generally improved with continued treatment. No new safety signals were identified beyond Phase 2.

TRIUMPH-4 used a gradual titration: starting at 1mg weekly, escalating through 2mg, 4mg, 8mg, and reaching the maintenance dose of 12mg. Each titration step lasted approximately 4 weeks. This slow escalation helps minimize gastrointestinal side effects by allowing the body to adapt.

While full metabolic data from TRIUMPH-4 are awaited, Phase 2 data showed retatrutide significantly improved HbA1c, reduced liver fat (by up to 86% per TRIUMPH-3 MASLD sub-study), improved lipid profiles (LDL, triglycerides, HDL), and reduced waist circumference. The glucagon receptor component may provide particular benefits for liver fat reduction.

Based on TRIUMPH-4 results, Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential approval in 2027. The EMA filing is expected to follow. Additional data from TRIUMPH-1 (obesity + T2D), TRIUMPH-2 (cardiovascular outcomes), TRIUMPH-3 (MASLD), and TRIUMPH-5 (maintenance) will further define the drug's profile.

AllPeptides.eu maintains research protocols for Retatrutide at 5mg, 10mg, 20mg, and 30mg vial sizes, with complete reconstitution guides, dosing tables, and cycle calculations. These are educational resources for researchers — not medical prescriptions.